HUP9802945A2 - 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására - Google Patents
1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállításáraInfo
- Publication number
- HUP9802945A2 HUP9802945A2 HU9802945A HUP9802945A HUP9802945A2 HU P9802945 A2 HUP9802945 A2 HU P9802945A2 HU 9802945 A HU9802945 A HU 9802945A HU P9802945 A HUP9802945 A HU P9802945A HU P9802945 A2 HUP9802945 A2 HU P9802945A2
- Authority
- HU
- Hungary
- Prior art keywords
- naphth
- tetrahydropyridine
- lateral sclerosis
- amyotrophic lateral
- ylethyl
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 abstract 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 abstract 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 abstract 1
- 102000013275 Somatomedins Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
A találmány a 1-[2-(naft-2-il)-etil]-4-[3-(triflűőr-metil)-fenil]-1,2,3,6-tetrahidrő-piridin vagy annak gyógyászatilag elfőgadhatósavakkal alkőtőtt addíciós sói alkalmazására vőnatkőzik izőmsőrvadásőslaterális szklerózis (ALS) kezelésére alkalmas gyógyszerelőállítására, önmagában, vagy 2-aminő-6-(triflűőr-metőxi)-benzőtiazőllal, illetve IGF-1-gyel vagy BDNF-fel kőmbinációban, ahőlaz IGF-1 inzűlinszerű növekedési faktőr 1-et, a BDNF agyból származóneűrőtróf faktőrt jelent. ŕ
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9512635A FR2740343B1 (fr) | 1995-10-26 | 1995-10-26 | Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
FR9607336 | 1996-06-13 | ||
PCT/FR1996/001674 WO1997015304A1 (fr) | 1995-10-26 | 1996-10-25 | Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP9802945A2 true HUP9802945A2 (hu) | 1999-04-28 |
HUP9802945A3 HUP9802945A3 (en) | 1999-05-28 |
HU222039B1 HU222039B1 (hu) | 2003-03-28 |
Family
ID=26232287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9802945A HU222039B1 (hu) | 1995-10-26 | 1996-10-25 | 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására |
Country Status (28)
Country | Link |
---|---|
US (1) | US6043251A (hu) |
EP (1) | EP0866704B1 (hu) |
JP (1) | JP3468526B2 (hu) |
KR (1) | KR100472793B1 (hu) |
CN (1) | CN1104241C (hu) |
AT (1) | ATE200423T1 (hu) |
AU (1) | AU719342B2 (hu) |
BR (1) | BR9611124A (hu) |
CA (1) | CA2235747C (hu) |
CY (1) | CY2279B1 (hu) |
CZ (1) | CZ293360B6 (hu) |
DE (1) | DE69612510T2 (hu) |
DK (1) | DK0866704T3 (hu) |
EE (1) | EE04177B1 (hu) |
ES (1) | ES2159362T3 (hu) |
GR (1) | GR3036027T3 (hu) |
HK (1) | HK1016904A1 (hu) |
HU (1) | HU222039B1 (hu) |
IL (1) | IL124091A (hu) |
IS (1) | IS1961B (hu) |
NO (1) | NO316256B1 (hu) |
NZ (1) | NZ320355A (hu) |
PT (1) | PT866704E (hu) |
SI (1) | SI0866704T1 (hu) |
SK (1) | SK284099B6 (hu) |
TR (1) | TR199800717T2 (hu) |
UA (1) | UA57004C2 (hu) |
WO (1) | WO1997015304A1 (hu) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2782008B1 (fr) * | 1998-08-07 | 2003-04-25 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique |
US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
EP2246053B1 (en) * | 2001-12-11 | 2013-09-18 | University Of Virginia Patent Foundation | Use of pramipexole to treat amyotrophic lateral sclerosis |
KR101130212B1 (ko) * | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
ES2334061T3 (es) * | 2005-08-15 | 2010-03-04 | University Of Virginia Patent Foundation | Neurorrestauracion con pramipexol r(+). |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
ATE537826T1 (de) | 2006-05-16 | 2012-01-15 | Knopp Neurosciences Inc | Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
RU2454409C2 (ru) | 2007-03-14 | 2012-06-27 | Нопп Ньюросайенсиз, Инк. | Синтез хирально очищенных замещенных бензотиазолдиаминов |
EP2334185A4 (en) * | 2008-08-19 | 2011-09-21 | Knopp Neurosciences Inc | COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
SI3019167T1 (sl) | 2013-07-12 | 2021-04-30 | Knopp Biosciences Llc | Zdravljenje povišanih ravni eozinofilcev in / ali bazofilcev |
US9642840B2 (en) | 2013-08-13 | 2017-05-09 | Knopp Biosciences, Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
PL3033081T3 (pl) | 2013-08-13 | 2021-08-30 | Knopp Biosciences Llc | Kompozycje i sposoby do leczenia przewlekłej pokrzywki |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2662355B1 (fr) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
FR2672213B1 (fr) * | 1991-02-05 | 1995-03-10 | Sanofi Sa | Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres. |
FR2672731A1 (fr) * | 1991-02-07 | 1992-08-14 | France Telecom | Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant. |
FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
-
1996
- 1996-10-25 CA CA002235747A patent/CA2235747C/en not_active Expired - Fee Related
- 1996-10-25 IL IL12409196A patent/IL124091A/xx not_active IP Right Cessation
- 1996-10-25 KR KR10-1998-0702997A patent/KR100472793B1/ko not_active IP Right Cessation
- 1996-10-25 CN CN96198508A patent/CN1104241C/zh not_active Expired - Fee Related
- 1996-10-25 SK SK526-98A patent/SK284099B6/sk unknown
- 1996-10-25 ES ES96934975T patent/ES2159362T3/es not_active Expired - Lifetime
- 1996-10-25 JP JP51637097A patent/JP3468526B2/ja not_active Expired - Fee Related
- 1996-10-25 PT PT96934975T patent/PT866704E/pt unknown
- 1996-10-25 DK DK96934975T patent/DK0866704T3/da active
- 1996-10-25 CZ CZ19981296A patent/CZ293360B6/cs not_active IP Right Cessation
- 1996-10-25 BR BR9611124A patent/BR9611124A/pt not_active Application Discontinuation
- 1996-10-25 WO PCT/FR1996/001674 patent/WO1997015304A1/fr active IP Right Grant
- 1996-10-25 HU HU9802945A patent/HU222039B1/hu not_active IP Right Cessation
- 1996-10-25 AU AU73084/96A patent/AU719342B2/en not_active Ceased
- 1996-10-25 AT AT96934975T patent/ATE200423T1/de not_active IP Right Cessation
- 1996-10-25 TR TR1998/00717T patent/TR199800717T2/xx unknown
- 1996-10-25 NZ NZ320355A patent/NZ320355A/xx unknown
- 1996-10-25 UA UA98042073A patent/UA57004C2/uk unknown
- 1996-10-25 US US09/051,740 patent/US6043251A/en not_active Expired - Fee Related
- 1996-10-25 DE DE69612510T patent/DE69612510T2/de not_active Expired - Fee Related
- 1996-10-25 EP EP96934975A patent/EP0866704B1/fr not_active Expired - Lifetime
- 1996-10-25 EE EE9800132A patent/EE04177B1/xx not_active IP Right Cessation
- 1996-10-25 SI SI9630299T patent/SI0866704T1/xx unknown
-
1998
- 1998-04-21 IS IS4722A patent/IS1961B/is unknown
- 1998-04-24 NO NO19981856A patent/NO316256B1/no unknown
-
1999
- 1999-05-24 HK HK99102262A patent/HK1016904A1/xx not_active IP Right Cessation
-
2001
- 2001-06-13 GR GR20010400880T patent/GR3036027T3/el not_active IP Right Cessation
-
2002
- 2002-05-15 CY CY0200033A patent/CY2279B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9802945A2 (hu) | 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására | |
UA40587C2 (uk) | Метансульфонат (е)-3-[2-h-бутил-1{(4-карбоксифеніл)метил}-1н-імідазол-5-іл]-2-(2-тієніл)метил-2-пропенової кислоти, спосіб його одержання, фармацевтична композиція на його основі | |
ATE238280T1 (de) | Verwendung eines pharmazeutisch geeigneten salzes von (3r,2'r)-3-((cyclopentyl- hydroxyphenylacetyl)oxy)-1,1-dimethyl- pyrrolidinium zur herstellung eines arzneimittels | |
ATE232864T1 (de) | Benzonaphthyridine | |
EP0410114A3 (en) | Use of 4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain | |
DE59607887D1 (de) | Verfahren zur herstellung von optisch aktivem 1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisochinolin | |
DE69231883T2 (de) | 4-(1,1-Dialkoxycarbonyl-Alkyl)Azetidin-2-on-Derivate zur Herstellung von 4-(1-Carboxy-Alkyl)Azetidin-2-on-Derivaten | |
ATE100451T1 (de) | Substituierte bisazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
ATE156490T1 (de) | Neue hydrazino und hydroxyamino-14-beta- hydroxyandrostan-derivate mit kardiotonischer aktivität, ein verfahren zu ihrer herstellung und pharmaceutische präparate davon | |
DE69432000T2 (de) | Verwendung von Tetrahydropyridinderivaten zur Herstellung von Kardioprotektiven Medikamenten | |
ATE123766T1 (de) | Verfahren zur herstellung von trisubstituierten benzoesäuren und zwischenprodukte. | |
NO20022778D0 (no) | Fremgangsmåte for fremstilling av 2-(2-brometyl)-naftalen | |
DE50000896D1 (de) | Verfahren zur Herstellung von Pyrrolen | |
DE59605367D1 (de) | Verwendung des alpha,alpha-diphenylessigsäure-4-(n-methyl-piperidyl)esters als spasmoanalgetikum | |
DE59010873D1 (de) | Verwendung von N-(Aminoacyl)-aminosäuren zur Herstellung von dopaminergen und gonadotropen Arzneimitteln. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HFG4 | Patent granted, date of granting |
Effective date: 20030127 |
|
HPC4 | Succession in title of patentee |
Owner name: SANOFI-SYNTHELABO, FR |
|
MM4A | Lapse of definitive patent protection due to non-payment of fees |